taxotere lawsuit

 

 

VICTORIA MANIATIS LEADS LITIGATION

Victoria Maniatis, Partner, Sanders Phillips Grossman Taxotere Docetaxel Litigation Attorney
Victoria Maniatis, Partner, Sanders Phillips Grossman Taxotere Docetaxel Litigation Attorney

Victoria Maniatis leads Sanders Phillips Grossman’s Taxotere Docetaxel hair loss litigation team. She is passionate about women’s health issues and has many years of experience in mass tort litigation, concentrating specifically on pharmaceutical and medical device claims.

Both federal and state judges have appointed Ms. Maniatis as lead counsel on various Plaintiffs’ steering committees, including Fosamax Femur Fracture litigation as well as the Bard, Boston Scientific, Ethicon, and American Medical Systems cases within the Transvaginal Mesh litigation. She is lead counsel in New Jersey’s Propecia Multi-County litigation.

She is one of the founding members of the Mass Tort Medical School’s annual medical seminar for Plaintiffs’ attorneys and committee co-chair for the Women en Masse mass tort group.

Ms. Maniatis is also an avid triathlete and has one son.

Read more about our Sanders Phillips Grossman attorneys here.

 

IS THIS A CLASS ACTION LAWSUIT?

No.  The litigation against Sanofi-Aventis is proceeding as a mass tort. That means each woman we represent will have her own individual claim against the drug manufacturer for her own distinct damages because the nature and extent of injuries are separate and distinct. We will negotiate settlements considering the facts of each individual case to ensure compensation to the degree of damages suffered.  Damages typically include such things as pain and suffering, loss of enjoyment of life, loss of consortium, medical expenses, wage loss, and more.

In a class action, all plaintiffs have the same or similar damages.  An example would be consumers who purchased the same defective product, such as a washing machine with a defective part.  A class action will bring thousands of victims together and aggregate claims where it may be impractical to efficiently pursue claims individually.

Sanders Phillips Grossman is currently accepting cases from women across the United States and Puerto Rico who underwent chemotherapy at some point between 2006 – 2016 and suffered permanent baldness or hair loss that lasted two or more months after treatment.  A successful outcome of your claim could entitle you to damages for medical expenses, wage loss, pain and suffering, loss of enjoyment of life, and loss of consortium.

 

FEDERAL LAWSUIT FILED MARCH, 2016

A federal lawsuit has been filed in the state of California by a woman who blames her permanent hair loss on the popular breast cancer chemotherapy drug, Taxotere (docetaxel). Ami Dodson claims the drug manufacturer and corporate giant, Sanofi-Aventis, engaged in a fraudulent marketing scheme to drive sales while hiding this serious side effect of the drug.

“Defendants [preyed] on one of the most vulnerable groups of individuals at the most difficult time in their lives,” Dodson said in the lawsuit. “Defendants obtained billions of dollars in increased revenues at the expense of unwary cancer victims simply hoping to survive their condition and return to a normal life.”  With other chemotherapy drugs widely available, she says she would not have used the drug had she been made aware of the potential side effect.

“Permanent baldness is a disfiguring condition, especially for women,” said Dodson. “Women who experienced disfiguring permanent alopecia as a result of the use of Taxotere suffer great mental anguish as well as economic damages, including but not limited to loss of work or inability to work due to significant psychological damage.”

It has been alleged that Sanofi-Aventis knew as early as the late 1990’s that Taxotere could cause permanent hair loss but went to great lengths to hide the problem.  The claim also cites a warning letter issued by the FDA in 2009, as the company continued to market the drugs’ “superior efficacy” although a 2008 study published by the New England Journal of Medicine concluded that a competing drug was actually more effective for certain patients.

 

SANOFI-AVENTIS’S OTHER LEGAL MATTERS

Sanofi-Aventis has a history of allegations of illegal activities.

As reported by CNBC, “In 2012, Sanofi agreed to pay the federal government $109 million to resolve allegations that the company violated the False Claims Act by giving physicians free units of the knee injection Hyalgan in order to induce them to buy and prescribe the drug, in violation of the Anti-Kickback Statute.”

CNBC also reported that “In March 2013, two ex-Sanofi employees were sentenced by a court in Germany to suspended sentences, and Sanofi was fined 28 million euros ($29.8 million) in connection with a bribery case there. A spokesman for prosecutors told the Reuters news agency that the former employees made illicit payments to a consulting company that was advising a Sanofi client in order to get the client to order more drugs from Sanofi.”

Ex-employee Diane Ponte, paralegal, in a pending whistleblower lawsuit against the company, stated by written affadavit in Newark, New Jersey “prior to my last position with Sanofi, I had been working in the Sanofi litigation department for approximately seven years. In the course of my working in the Sanofi litigation department, I became personally aware of many instances in which documents were deliberately destroyed by Sanofi attorneys to avoid turning over said documents in discovery.”

DO YOU HAVE A CLAIM FOR A CASH SETTLEMENT?

Sanders Phillips Grossman is currently accepting cases from women across the United States and Puerto Rico who underwent chemotherapy at some point between 2006 – 2016 and suffered permanent baldness or hair loss that lasted two or more months after treatment.  A successful outcome of your claim could entitle you to damages for medical expenses, wage loss, pain and suffering, loss of enjoyment of life, and loss of consortium.

 

LEADERSHIP ROLES IN PHARMACEUTICAL CLAIMS

Sanders Phillips Grossman is a national law firm representing consumers who have been harmed by defective drugs and medical devices.  We have been holding pharmaceutical companies responsible and protecting victims’ rights for over 30 years. Defective drugs are pharmaceuticals with side effects that potentially harm, injure, or kill the patient to the point that they outweigh the drug’s intended benefits. Defective devices, such as faulty prosthetics, implants, pacemakers, or surgical instruments can harm patients when the product is defective in the manufacturing process, design, or marketing strategy.

Pharmaceutical companies are some of the largest, wealthiest, and most influential corporate entities in the world.  As a nationally recognized leading plaintiff’s law firm, Sanders Phillips Grossman and its predecessors have recovered over one billion dollars for injured consumers.  Our attorneys are experienced, trusted, and aggressive. Our history in dealing with these types of claims has allowed us to take leadership roles in many national defective drug and device litigations.

Our attorneys have extensive knowledge of pharmaceutical and medical device regulations. We have working knowledge of pharmaceutical product pre-approval development, with a detailed understanding of Non-Clinical Studies and Clinical Trials, and post-approval obligations and requirements, including Safety Surveillance and Pharmacovigilance and ongoing Clinical Trials.  We understand the FDA-drug sponsor relationships which enable us to tailor successful strategies and arguments in discovery battles in order to procure materials Plaintiffs and their experts need.   We have held leadership roles in all facets of litigation in coordinated proceedings, with a particular focus on developing the building blocks to establish General Causation, which is often times the most difficult obstacle to hurdle in a pharmaceutical case.

 

SOME OF OUR EXPERTISE INCLUDES:

  • Lead Counsel Position in the Vioxx litigation which ultimately led Merck to agree to one of the largest Civil Settlements in American History for $4.85 billion.
  • Liaison to the media as a member of the Vioxx PSC’s Public Relations Committee, and as a liaison for the Committee to many financial institutions and governmental agencies.
  • Lead the Trial Team in Rosenberg v. Merck, the first bellwether New Jersey Trial in Atlantic County Superior Court, after an $8 million verdict in Boles v. Merck for a victim of Fosamax.
  • Member of Steering Committee in Zimmer Nextgen Knee Multi-District litigation, leading negotiations for developing the Case Management Order for Electronic Storage Information (ESI).
  • Led negotiations for the Electronic Discovery protocol for the Propecia Multi-District Litigation (MDL) in the Eastern District of New York.
  • Steering Committee in the In Re Fresenius Granuflo/Naturalyte Dialysate Products Liability Litigation in the District of Massachusetts.
  • Steering Committee in the Mirena litigation in the Southern District of New York.
  • Plaintiffs Steering Committee in the following mass tort litigations: In Re Avandia, In ReChantix, In Re Zicam, and the New Jersey State Court Coordination of Levaquin.
  • Co-lead in the NY Chantix Coordination and the New Jersey Reglan Coordination, allTransvaginal Mesh PSC, and Propecia coordination.
  • Co-Lead Counsel in the Risperdal and Invega Product Liability Cases JCCP 4775 litigation, Plaintiff’s Liaison Counsel in the In Re Infusion Pain Pump JCCP 4615 litigation, the Plaintiff’s Steering Committee in the In Re Incretin Mimetics Product Liability Litigation MDL 2452, the Plaintiff’s Steering Committee in the In Re Zoloft Birth Defect Cases JCCP4771 and the Science Committee in the In re Fresenius Granuflo/Naturalyte DialysateProducts MDL 2428.
  • Discovery Committee in the Benical MDL in New Jersey and Mirena Litigation in New York and New Jersey
  • Legal commentator for several years on COURT TV – appearing on CATHERINE CRIER & COMPANYTRIAL HEAT and BOTH SIDES
  • Lectured for the Justices of the Supreme Court Appellate Terms, First and Second Departments, at the New York State Judicial Institute

Sanders Phillips Grossman has been holding pharmaceutical companies responsible for injuring individuals by their defective drugs and devices for over 30 years. Defective drugs are pharmaceuticals with side effects that potentially harm, injure, or kill the patient to the point that they outweigh the drug’s intended benefits. Defective devices, such as faulty prosthetics, implants, pacemakers, or surgical instruments can harm patients when the product is defective in the manufacturing process, design, or marketing strategy.

Pharmaceutical companies are some of the largest, wealthiest, and most influential corporate entities in the world. Sanders Phillips Grossman and its predecessors have recovered over one billion dollars for injured consumers. Our firm’s history in dealing with drug and medical device injury claims has allowed us to take leadership roles in many of the national defective drug and device litigations.

Nationally recognized as a leading plaintiff’s law firm, we handle cases in all 50 states and Puerto Rico.

Read more about our attorneys here.

Victoria Maniatis Leads Litigation

Victoria Maniatis, Partner, Sanders Phillips Grossman Taxotere Docetaxel Litigation Attorney
Victoria Maniatis, Partner, Sanders Phillips Grossman Taxotere Docetaxel Litigation Attorney

Victoria Maniatis leads Sanders Phillips Grossman’s Taxotere Docetaxel hair loss litigation team. She is passionate about women’s health issues and has many years of experience in mass tort litigation, concentrating specifically on pharmaceutical and medical device claims.

Both federal and state judges have appointed Ms. Maniatis as lead counsel on various Plaintiffs’ steering committees, including Fosamax Femur Fracture litigation as well as the Bard, Boston Scientific, Ethicon, and American Medical Systems cases within the Transvaginal Mesh litigation. She is lead counsel in New Jersey’s Propecia Multi-County litigation.

She is one of the founding members of the Mass Tort Medical School’s annual medical seminar for Plaintiffs’ attorneys and committee co-chair for the Women en Masse mass tort group.

Ms. Maniatis is also an avid triathlete and has one son.

Read more about our Sanders Phillips Grossman attorneys here.

 

Get a free case review
We are standing by 24/7, waiting to assist you.

 

Is this a class action lawsuit?

No.  The litigation against Sanofi-Aventis is proceeding as a mass tort. That means each woman we represent will have her own individual claim against the drug manufacturer for her own distinct damages, because the nature and extent of injuries are separate and distinct. We will negotiate settlements considering the facts of each individual case to ensure compensation to the degree of damages suffered.  Damages typically include such things as pain and suffering, loss of enjoyment of life, loss of consortium, medical expenses, wage loss and more.

In a class action, all plaintiffs have the same or similar damages.  An example would be consumers who purchased the same defective product, such as a washing machine with a defective part.  A class action will bring thousands of victims together and aggregate claims where it may be impractical to efficiently pursue claims individually.

Sanders Phillips Grossman is currently accepting cases from women across the United States and Puerto Rico who underwent chemotherapy at some point between 2006 – 2016 and suffered permanent baldness or hair loss that lasted two or more months after treatment.  A successful outcome of your claim could entitle you to damages for medical expenses, wage loss, pain and suffering, loss of enjoyment of life, and loss of consortium.

 

Get a free case review
We are standing by 24/7, waiting to assist you.

 

federal lawsuit filed march, 2016

A federal lawsuit has been filed in the state of California by a woman who blames her permanent hair loss on the popular breast cancer chemotherapy drug, Taxotere (docetaxel). Ami Dodson claims the drug manufacturer and corporate giant, Sanofi-Aventis, engaged in a fraudulent marketing scheme to drive sales while hiding this serious side effect of the drug.

“Defendants [preyed] on one of the most vulnerable groups of individuals at the most difficult time in their lives,” Dodson said in the lawsuit. “Defendants obtained billions of dollars in increased revenues at the expense of unwary cancer victims simply hoping to survive their condition and return to a normal life.”  With other chemotherapy drugs widely available, she says she would not have used the drug had she been made aware of the potential side effect.

“Permanent baldness is a disfiguring condition, especially for women,” said Dodson. “Women who experienced disfiguring permanent alopecia as a result of the use of Taxotere suffer great mental anguish as well as economic damages, including but not limited to loss of work or inability to work due to significant psychological damage.”

It has been alleged that Sanofi-Aventis knew as early as the late 1990’s that Taxotere could cause permanent hair loss but went to great lengths to hide the problem.  The claim also cites a warning letter issued by the FDA in 2009, as the company continued to market the drugs’ “superior efficacy” although a 2008 study published by the New England Journal of Medicine concluded that a competing drug was actually more effective for certain patients.

Sanofi-Aventis's Other Legal Matters

Sanofi-Aventis has a history of allegations of illegal activities.

As reported by CNBC, “In 2012, Sanofi agreed to pay the federal government $109 million to resolve allegations that the company violated the False Claims Act by giving physicians free units of the knee injection Hyalgan in order to induce them to buy and prescribe the drug, in violation of the Anti-Kickback Statute.”

CNBC also reported that “In March 2013, two ex-Sanofi employees were sentenced by a court in Germany to suspended sentences, and Sanofi was fined 28 million euros ($29.8 million) in connection with a bribery case there. A spokesman for prosecutors told the Reuters news agency that the former employees made illicit payments to a consulting company that was advising a Sanofi client in order to get the client to order more drugs from Sanofi.”

Ex-employee Diane Ponte, paralegal, in a pending whistleblower lawsuit against the company, stated by written affadavit in Newark, New Jersey “prior to my last position with Sanofi, I had been working in the Sanofi litigation department for approximately seven years. In the course of my working in the Sanofi litigation department, I became personally aware of many instances in which documents were deliberately destroyed by Sanofi attorneys to avoid turning over said documents in discovery.”

Do you have a claim for a cash settlement?

Sanders Phillips Grossman is currently accepting cases from women across the United States and Puerto Rico who underwent chemotherapy at some point between 2006 – 2016 and suffered permanent baldness or hair loss that lasted two or more months after treatment.  A successful outcome of your claim could entitle you to damages for medical expenses, wage loss, pain and suffering, loss of enjoyment of life, and loss of consortium.

Get a free case review
We are standing by 24/7, waiting to assist you.

 

leadership roles in pharmaceutical claims

Sanders Phillips Grossman is a national law firm representing consumers who have been harmed by defective drugs and medical devices.  We have been holding pharmaceutical companies responsible and protecting victims’ rights for over 30 years. Defective drugs are pharmaceuticals with side effects that potentially harm, injure, or kill the patient to the point that they outweigh the drug’s intended benefits. Defective devices, such as faulty prosthetics, implants, pacemakers or surgical instruments can harm patients when the product is defective in the manufacturing process, design or marketing strategy.

Pharmaceutical companies are some of the largest, wealthiest, and most influential corporate entities in the world.  As a nationally recognized leading plaintiff’s law firm, Sanders Phillips Grossman and its predecessors have recovered over one billion dollars for injured consumers.  Our attorneys are experienced, trusted and aggressive. Our history in dealing with these types of claims has allowed us to take leadership roles in many national defective drug and device litigations.

Our attorneys have extensive knowledge of pharmaceutical and medical device regulations. We have working knowledge of pharmaceutical product pre-approval development, with detailed understanding on Non-Clinical Studies and Clinical Trials, and post-approval obligations and requirements, including Safety Surveillance and Pharmacovigilance and ongoing Clinical Trials.  We understand the FDA-drug sponsor relationships which enable us to tailor successful strategies and arguments in discovery battles in order to procure materials Plaintiffs and their experts need.   We have held leadership roles in all facets of litigation in coordinated proceedings, with a particular focus on developing the building blocks to establish General Causation, which is often times the most difficult obstacle to hurdle in a pharmaceutical case.

SOME OF OUR EXPERTISE INCLUDES:

  • Lead Council Position in the Vioxx litigation which ultimately led Merck to agree to one of the largest Civil Settlements in American History for $4.85 billion.
  • Liaison to the media as a member of the Vioxx PSC’s Public Relations Committee, and as a liaison for the Committee to many financial institutions and governmental agencies.
  • Lead the Trial Team in Rosenberg v. Merck, the first bellwhether New Jersey Trial in Atlantic County Superior Court, after an $8 million verdict in Boles v. Merck for a victim ofFosamax.
  • Member of Steering Committee in Zimmer Nextgen Knee Multi-District litigation, leading negotiations for developing the Case Management Order for Electronic Storage Information (ESI).
  • Led negotiations for the Electronic Discovery protocol for the Propecia Multi-District Litigation (MDL) in the Eastern District of New York.
  • Steering Committee in the In Re Fresenius Granuflo/Naturalyte Dialysate Prodcuts Liability Litigation in the District of Massachusetts.
  • Steering Committee in the Mirena litigation in the Southern District of New York.
  • Plaintiffs Steering Committee in the following mass tort litigations: In Re Avandia, In ReChantix, In Re Zicam, and the New Jersey State Court Coordination of Levaquin.
  • Co-lead in the NY Chantix Coordination and the New Jersey Reglan Coordination, allTransvaginal Mesh PSC, and Propecia coordination.
  • Co-Lead Counsel in the Risperdal and Invega Product Liability Cases JCCP 4775 litigation, Plaintiff’s Liaison Counsel in the In Re Infusion Pain Pump JCCP 4615 litigation, the Plaintiff’s Steering Committee in the In Re Incretin Mimetics Product Liability Litigation MDL 2452, the Plaintiff’s Steering Committee in the In Re Zoloft Birth Defect Cases JCCP4771 and the Science Committee in the In re Fresenius Granuflo/Naturalyte DialysateProducts MDL 2428.
  • Discovery Committee in the Benical MDL in New Jersey and Mirena Litigation in New York and New Jersey
  • Legal commentator for several years on COURT TV – appearing on CATHERINE CRIER & COMPANY, TRIAL HEAT and BOTH SIDES
  • Lectured for the Justices of the Supreme Court Appellate Terms, First and Second Departments, at the New York State Judicial Institute

Sanders Phillips Grossman has been holding pharmaceutical companies responsible for injuring individuals by their defective drugs and devices for over 30 years. Defective drugs are pharmaceuticals with side effects that potentially harm, injure, or kill the patient to the point that they outweigh the drug’s intended benefits. Defective devices, such as faulty prosthetics, implants, pacemakers or surgical instruments can harm patients when the product is defective in the manufacturing process, design or marketing strategy.

Pharmaceutical companies are some of the largest, wealthiest, and most influential corporate entities in the world. Sanders Phillips Grossman and its predecessors have recovered over one billion dollars for injured consumers. Our firm’s history in dealing with drug and medical device injury claims has allowed us to take leadership roles in many of the national defective drug and device litigations.

Nationally recognized as a leading plaintiff’s law firm, we handle cases in all 50 states and Puerto Rico.

Read more about our attorneys here.